Table 1
Summary of clinical and laboratory findings
| No. | Age/Sex | Fever | Arthralgia/ arthritis | Rash | LAP | H/S | WBC (% of granulocyte)† | RF | ANA | W ESR (mm/hr) | Ferritin (ng/ml) | AST/ALT (IU/l) | LDH(IU/l) | F/U (Mo) | Type of LAP¶ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, alanine aminotransferase; ANA, antinuclear antibody; AST, aspartate aminotransferase; F/U, follow up; H/S, hepatomegaly/splenomegaly; LAP, multiple lymphadenopathy; LDH, lactate dehydrogenase; Mo, months; NA, not available; No., patient number; oligo, oilgoarticular (2 to 4 joints affected); poly, polyarticular (5 or more joints affected); RF, rheumatoid factor; WBC, white blood cell count; W ESR, Westergren erythrocyte sedimentation rate. | |||||||||||||||
| Westergren ESR: normal range, 0–20 mm/hr; ferritin: normal range, 10–300 ng/ml; AST/ALT: normal range, 0–40 IU/litre; LDH: normal range, 100–225 IU/litre. | |||||||||||||||
| *Positive at the dilution factor shown. †WBC in units of ×109 cells/litre (normal range, 4–10×109 cells/litre). ¶Type of LAP, type of lymphadenopathy; I, atypical paracortical hyperplasia pattern; II, burnt out histiocytic pattern; III, exuberant immunoblastic reaction pattern; IV, follicular hyperplasia pattern. | |||||||||||||||
| 1 | 37/F | + | +, poly | + | + | −/− | 16.60 (82%) | – | 1/40* | 12.6 | 18440 | 40/13 | 846 | 98 | I |
| 2 | 32/F | + | +, poly | + | + | −/+ | 16.05 (83%) | – | – | 103 | 1630 | 176/63 | 362 | 28 | I |
| 3 | 19/F | + | +, poly | + | + | +/+ | 16.11 (85%) | – | – | 53 | 222 | 31/10 | 549 | 37 | I |
| 4 | 24/F | + | +, poly | + | + | −/− | 17.29 (78%) | – | – | 131 | 109 | 53/59 | 690 | 26 | I |
| 5 | 40/F | + | +, oligo | + | + | −/+ | 32.20 (93%) | 1/20* | – | 40 | 15500 | 1605/563 | 282 | 6 | I |
| 6 | 39/F | + | +, poly | + | + | +/+ | 24.40 (84%) | – | 1/40* | 37 | 779 | NA | NA | 69 | II |
| 7 | 21/M | + | +, oligo | + | + | +/+ | 18.10 (90%) | – | – | 55 | 21700 | 117/102 | 662 | 5 | II |
| 8 | 18/F | + | +, poly | + | + | −/− | 19.40 (80%) | – | – | 63 | 2980 | 142/226 | NA | 96 | III |
| 9 | 29/M | + | +, oligo | + | + | +/+ | 21.40 (94%) | – | – | 76 | 31714 | 100/63 | 652 | 60 | III |
| 10 | 28/F | + | – | + | + | +/− | 18.70 (87%) | – | – | 85 | 1000 | 218/101 | 1294 | 28 | III |
| 11 | 26/F | + | +, poly | + | + | −/− | 15.51 (80%) | – | – | 132 | 7870 | 30/13 | 637 | 16 | IV |
| 12 | 15/M | + | +, poly | + | + | +/+ | 27.82 (86%) | – | – | 136 | 23500 | 101/11 | 362 | 5 | IV to I |
